Medication adherence among patients with comorbid diabetes.
R. Okwemba,E. Medvedeva,Andrew Wang
DOI: https://doi.org/10.1176/appi.ps.004982012
2013-09-01
Psychiatric Services
Abstract:Illness insight was measured with the Schedule of Assessment of Insight– Expanded, perceived coercion with a 15-item questionnaire, and symptom severity with the 24-item version of the Brief Psychiatric Rating Scale. Erasmus University Medical Center’s Medical Ethics Committee approved the study, and all participants provided informed consent. At baseline, patients from ethnic minority groups were younger than Dutch native patients (AntilleanSurinamese, 31.269.9 years; TurkishMoroccan, 27.067.1; and Dutch native, 42.9615.8 years; F520.25, df52 and 138, p,.001). Larger proportions of the ethnic minority groups had a psychotic disorder (AntilleanSurinamese, 92%, N533; TurkishMoroccan, 90%, N528; and Dutch native, 66%, N549; x512.66, df52, p5.002). No significant betweengroup differences were found in service engagement, illness insight, perceived coercion, and symptom severity. Mixed-model regression analyses showed a significant increase in engagement during follow-up (time b 521.34, SE5.28, p,.05; time b5–.05, SE5.02, p,.05). Better illness insight was correlated with greater engagement (b5–.91, SE5.17, p,.05). Over the follow-up period, engagement deteriorated among patients with more severe symptoms (b5–.05, SE5.06; by time b5.02, SE5.01, p,.05) and among patients with high levels of perceived coercion, although this effect became weaker over time (perceived coercion b5.10, SE5.06; by time b5.05, SE5.02, p,.05; by time b5–.004, SE5.002, p,.05). No significant relationship was found between ethnicity and the course of engagement during followup. This prospective study showed that ethnicity per se was not related to service engagement among involuntarily committed patients, either at baseline or during follow-up. The increase in engagement during followup was related to better illness insight and coincided with less perceived coercion and severity of symptoms. David Vinkers, M.D., Ph.D. Anton W. B. van Baars, M.D. André I. Wierdsma, Ph.D.